Close Menu

NEW YORK –  Merck said this week that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended that the European label for pembrolizumab (Keytruda) in urothelial carcinoma be updated to include data from the Phase III Keynote-361 trial, which investigated whether adding chemotherapy to pembrolizumab improved outcomes in patients but failed to meet key endpoints.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.